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Introduction
Burn injury is a common cause of morbidity and 
mortality. In Iran, approximately 30 000 people with 
burns present to the emergency departments each 
year. Among these, 3 000 dies and others either have 
minor burn injuries that are treated primarily in the 
emergency department or sustain major burn injuries 
that require hospital admission. Both impose the health 
systems a burden of cost. These numbers are eight times 
larger than the world average and therefore are a source 
of concern (Karimi et al. 2015).
In most cases, the bacterial infection of burn wounds 
is an unquestionable phenomenon because of the skin 
destruction, which plays a role of the major barrier to 
bacterial access to the internal tissues. Gram-positive 
bacteria including Staphylococcus aureus, β-hemolytic 
Streptococci and Enterococci, and Gram-negative bac-
teria such as Pseudomonas aeruginosa, Acinetobacter 
baumannii and Enterobacteriaceae are among the most 
frequent etiological agents of burn patients infections 
(Norbury et al. 2016).
The facultative anaerobic Gram-positive Enterococ-
cus spp. normally colonize the gastrointestinal tract, 
oral cavity, and vaginal tract. Enterococci are among 
the major agents associated with nosocomial infections 
particularly in burn patients presenting with bactere-
mia, urinary tract infections and endocarditis (Hashem 
et al. 2017). The US National Nosocomial Infection Sur-
veillance (NNIS) system, has ranked Enterococci among 
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A b s t r a c t
Enterococcus faecalis and Enterococcus faecium are among the main agents associated with nosocomial infections with high mortality in 
immunocompromised patients. Antibiotic resistance, especially against gentamicin and vancomycin among Enterococci, is a risk factor 
that could increase the morbidity and mortality rate. 179 Enterococci isolates from burn patients were included in this study. Antibiotic 
susceptibility testing was done using the disk diffusion test and minimum inhibitory concentration (MIC) was evaluated by agar microdilu-
tion. Vancomycin and gentamicin resistance associated genes including vanA, vanB, vanC, aac (6’)-Ie aph(2’’), aph(3’)-IIIa and ant(4’)-Ia 
were detected by PCR and their statistical relation with antibiotic resistance was evaluated. E. faecalis was the more prevalent strain among 
our local isolates and showed a higher antibiotic resistance in comparison to E. faecium. Vancomycin had a good antibacterial effect on the 
Enterococcus spp. isolates; however, resistance to this antibiotic and a high-level gentamicin resistance (HLGR) phenotype were observed. 
Among van operon genes, vanA was the most prevalent gene and among the gentamicin resistance genes, aph (3’)-IIIa was more frequent. 
The HLGR Enterococci are a real challenge in nosocomial infections. Vancomycin is a key antibiotic to treat such infections but emergence 
of VRE in our region could be a real concern and, therefore, phenotypic and molecular surveillance must be considered.
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the top three most common pathogens of nosocomial 
infections and the leading cause of nosocomial infec-
tions in burn patients (Pan 2012). 
Enterococci are intrinsically resistant to multiple 
antibiotic agents: cephalosporins, penicillinase-resistant 
penicillins, and low concentrations of aminoglycosides 
(Hollenbeck and Rice 2012). Vancomycin remains the 
drug of choice to treat enterococcal infections but now-
adays vancomycin-resistant Enterococci (VRE) isolates 
are a  global challenge. Such infections are treated by 
a  combination of cell wall-active agents with amino-
glycosides that achieve synergistic bactericidal activ-
ity. Aminoglycoside antibiotics are positively charged, 
carbohydrate-containing molecules that find a clinical 
use for the treatment of infections caused by both Gram-
negative and Gram-positive bacteria (Miller et al. 2014). 
Two antibiotic resistance phenotypes among Enterococci 
including VRE and HLGR have emerged as important 
nosocomial causes throughout the world as well as in 
Iran (Sakoulas et al. 2013a; Emaneini et al. 2016; Osuka 
et al. 2016). Operon associated genes (van operon) are 
responsible for VRE emergence and are the best studied 
antibiotic resistance operon (Faron et al. 2016).
In contrast to the rest of aminoglycosides, gen-
tamicin is not inactivated by target insensitivity and 
enzymatic modification and, therefore, remained for 
many years the aminoglycoside often used to achieve 
synergistic killing of Enterococci. However, there are 
some variants of aminoglycosides modifying enzymes 
(AMEs) that can affect gentamicin (Garneau-Tsodikova 
and Labby 2016). 
There are limited studies regarding the simultaneous 
resistance to vancomycin and gentamicin in hospital-
ized burn patients in Iran and thereby, we aimed to 
follow up and monitor the antibiotic resistance pattern 
and the genes encoding resistance to these two anti-
biotics among Enterococcus spp. strains isolated from 
burn patients.
Experimental
Materials and Methods
Bacterial isolates. One hundred seventy-nine out 
of 628 bacterial isolates confirmed as Enterococcus spp. 
were isolated from different clinical specimens (wound 
biopsies and blood) of burned patients referred to 
Taleghani burn hospital (the only referral burn center 
in Ahvaz, Khuzestan province, Iran) during January 
2015 to 2016. All isolates were primary identified by 
conventional microbiological methods and confirmed 
by specific tests such as bile esculin hydrolysis and PYR 
(Pyrrolidinyl Aminopeptidase) Test. Sugar fermenta-
tion (arabinose and sorbitol) were used for characteri-
zation of Enterococcus species (Emaneini et al. 2016). 
Molecular confirmation of the species was done by 
screening for the ddlE (d-alanine-d-alanine ligase) gene 
(Dutka-Malen et al. 1995).
Antimicrobial susceptibility testing. Susceptibility 
to antimicrobial agents was determined by disk diffusion 
method according to CLSI crite ria using commercially 
available disks (Mast, UK) includ ing vancomycin, teico-
planin, gentamicin, chloramphenicol, linezolid, cipro-
floxacin, and amoxicillin. The Minimum Inhibitory Con - 
cen tration (MIC) against gentamicin and vancomycin 
were determined using two-fold serial agar dilution 
method with Mueller Hinton agar (Difco, USA) according 
to CLSI guidelines (CLSI 2015). E. faeca lis ATCC 29212 
and E. faecium IP 4107 (The Collection of Institut Pasteur, 
France) were used as quality control reference strains.
DNA extraction and PCR. DNA was extracted 
using the AccuPrep® Genomic DNA Extraction Kit 
(Bioneer, South Korea). The oligonucleotide primers 
used in this study are listed in Table I. For each sample, 
the PCR assay was performed to identify vanA, vanB, 
vanC genes for vanco mycin resistance and aac(6’)-Ie 
aph(2’’), aph(3’)-IIIa and ant(4’)-Ia genes for gentamicin 
van A GGGAAAACGACAATTGC
 GTACAATGCGGCCGTTA 732 Dutka-Malen et al. 1995
vanB ATG GGA AGC CGA TAG TC
 GAT TTC GTT CCT CGA CC 638 Dutka-Malen et al. 1995
vanC AAT CGT CAA TTC CTG CAT GT
 TAA TCG TGG AAT ACG GGT TTG 299 Dutka-Malen et al. 1995
aac(6’)-Ie aph(2’’) AGGAATTTATCGAAAATGGTAGAAAAG
 CACAATCGACTAAAGAGTACCAATC 369 Vakulenko et al. 2003
aph(3’)-IIIa GGCTAAAATGAGAATATCACCGG
 CTTTAAAAAATCATACAGCTCGCG 523 Vakulenko et al. 2003
ant(4’)-Ia CAAACTGCTAAATCGGTAGAAGCC
 GGAAAGTTGACCAGACATTACGAACT 294 Vakulenko et al. 2003
Table I
Primers used in this study.
Target gene Oligonucleotide sequences (5’-3’) Size of product (bp) Reference
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resistance. DNA amplification was carried out in a 
peqSTAR thermal cycler system using a defined pro-
tocol as described previously (Dutka-Malen et al. 1995; 
Vakulenko et al. 2003).
Statistical analysis. We used absolute and relative 
frequency to present descriptive statistics. Chi-Square 
test and also Fisher exact test (if it was necessary) used 
to explain analytical statistics. Data were analyzed by 
SPSS version 22.
Results
The patients referred to the hospital had different 
degrees of burn. From 628 bacterial isolates, isolated 
from patient referred to our hospital, 28.5% (179 iso-
lates) were confirmed as Enterococci and among them 
108 (60.3%) were Enterococcus faecalis and 71 (39.7%) 
were Enterococcus faecium. These species were iso-
lated from blood (29.6%) and wound (70.4%) of burn 
patients. The drug resistance pattern of the isolates 
against eight antibiotics including chloramphenicol, 
linezolid, ciprofloxacin, amoxicillin, teicoplanin, vanco-
mycin, and gentamicin is shown in Fig. 1. Overall, drug 
resistance of E. faecalis was significantly higher than 
that of E. faecium (p < 0.03). Among the aminoglyco-
sides, the highest resistance rate was against gentamicin, 
and was observed in 45% of the E. faecalis and 15% of 
the E. faecium isolates, respectively. The pre valence 
of resistance to amoxicillin and tetracycline came in the 
second and third positions. However, a good sensitivity 
was observed toward vancomycin.
The frequency of vancomycin resistance associated 
genes: vanA, vanB, vanC and gentamicin resistance 
associated genes: aph(3’)-IIIa, ant(4’)-Ia and aac(6’)-Ie 
aph(2’) in the two Enterococcus species is reported in 
Table II.
The vanA gene was the most frequent vancomycin 
associated gene and it was detected in 23 positive cases 
(12.8%). As shown in Table II, the vanA and vanB genes 
were detected simultaneously in 6 isolates. The van-
comycin MICs among VRE isolates ranged between 
64 mg/l and 1024 mg/l. There was not a significant cor-
relation between the presence of van operon genes and 
the vancomycin MICs.
Among the gentamicin resistance genes, the highest 
frequency was observed for aph(3’)-IIIa in 68% (n = 122) 
and aac(6’)-Ie aph(2’) in 61% (n = 109) of the cases.
The prevalence of aph(3’)-IIIa, ant(4’)-Ia and 
aac(6’)-Ie aph(2’) in HLGR isolates were 10.8%, 65.5% 
and 60.1% respectively.
The simultaneous presence of at least two genta-
micin resistance associated genes also were observed 
Fig. 1. Antibiotic resistance pattern of E. faecalis and E. faecium isolated in this study against eight antibacterial agents.
E. faecalis 14 3 3 1 74 8 67 3 26 6 4
E. faecium 9 0 3 2 48 10 42 6 50 2 1
Total (n) 23 3 6 3 122 18 109 9 76 8 5
Table II
Frequency of vancomycin and gentamicin resistance genes among our local Enterococci isolates.
Abbreviations are as follows: 3: aph (3’)-III;, 4’: ant (4’)-I;, 6’: aac (6’)-Ie aph (2’’)
Genus
van gene Gentamicin gene
vanA vanB vanA, vanB vanC 3’ 4’ 6’ 3’ + 4’ 3’ + 6’ 4’ + 6’ 3’ + 4’ + 6’
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and the most frequently, the simultaneous presence of 
aph(3’)-IIIa and aac(6’)-Ie aph(2’) genes wad detected 
on 109 cases (60.8%). There was no significant correla-
tion between aminoglycoside resistance emergence and 
the prevalence of these genes.
The relation between the aminoglycoside resist-
ance genes and the MIC of aminoglycosides antibiot-
ics is reported in Table III. Of 122 isolates that were 
harboring the aph(3’)-IIIa gene, 7.3% (n = 9) had the 
gentamicin MIC of ≥ 512 µg/ml. The gentamicin MICs 
for isolates harboring ant(4’)-Ia and aac(6’)-Ie aph (2’) 
were 3 µg/ml and 11 µg/ml respectively.
The HLGR phenotype was reported in 82.7% of the 
isolates in this study (57.4% of E. faecalis and 42.6% 
of E. faecium isolates, respectively). There was no signi-
ficant correlation between HLGR rate and the species 
of Enterococci (p = 0.2).
Discussion
We studied 179 Enterococci isolates from patients, 
which were referred to a burn center in Ahvaz, south-
west of Iran and this number is higher than other 
similar studies that could be a point for our study. The 
morbidity and mortality associated with nosocomial 
infections due to antimicrobial resistant Enterococci 
demonstrated a crude mortality rate of 17–100% in 
case of enterococcal bacteremia in different hospitals 
around the world (Edmond et al. 1996).
The clinical importance of Enterococci is directly 
related to their antibiotic resistance, which contributes 
to the risk of colonization and infection. The species 
of the greatest clinical importance are E. faecalis and 
E. faecium (Kajihara et al. 2015). In our study, E. faecalis 
was more prevalent, which is in concordance with other 
reports (Olawale et al. 2011; Komiyama et al. 2016). 
The increase of antimicrobial resistance among 
Enterococcus spp. is a serious health problem globally 
and there are several reports of antimicrobial resistance 
among Enterococci isolated from hospitalized patients 
in Iran and other countries (Emaneini et al. 2016; Lan 
et al. 2016). In this study, antibiotic resistance rate in 
E. faecalis isolates was significantly higher than E. fae-
cium. However, it has been reported that notwithstand-
ing of its lower frequency, E. faecium has a more ability 
to develop antibiotic resistance (Werner et al. 2008).
Although there are an increasing number of reports 
on VRE emergence in other countries, in the present 
study most of the isolates were susceptible to vancomy-
cin. This could be due to lower usage of vancomycin 
in the first place because treatment is done with other 
antibacterial agents. Moreover, the VRE phenotype is 
more often associated with E. faecium (Werner et al. 
2008; Arias et al. 2010), which was not prevalent in 
our study. The vanA and vanB genes are the most fre-
quently vancomycin resistance associated genes among 
Enterococcus spp. Enterococci which harbor the vanA 
gene, are resistant to vancomycin (MIC ≥ 64 µg/ml) and 
teicoplanin (MIC ≥ 8 µg/ml) at a high concentration. 
Resistance is induced by the presence of these drugs 
(Eliopoulos and Gold 2001). In our study the vanA gene 
was more prevalent but totally the vancomycin resist-
ance was observed only in 10.6% of the isolates, which 
accordingly to the ability of the resistance induction in 
the presence of the antibiotic, could be associated with 
lack of exposure to vancomycin and teicoplanin, as it 
was mentioned previously. The vanB harboring Entero-
cocci are resistant to a range of vancomycin concentra-
tions: from 4 to over 1024 µg/ml. Such strains remain 
susceptible to teicoplanin. The vanC gene was reported 
in E. gallinarum and E. casseliflavus, which are intrinsi-
cally resistant to vancomycin at concentrations typically 
lower than or equal to 32 µg/ml (Eliopoulos and Gold 
2001). In this study, we observed the vanC gene in three 
isolates and this gene could has been transmitted from 
these organisms to the clinically important E. faecalis 
and E. faecium spp. 
In addition to the costs imposed to health systems, 
the importance of the VRE emergence is that these 
strains could serve as a van genes reservoir for other 
organisms, especially Staphylococcus aureus. This could 
be a real problem because vancomycin is the therapeu-
tic agent of choice for methicillin-resistant S. aureus 
(Gardete and Tomasz 2014). 
For the first time, the HLGR phenotype was reported 
in E. faecalis in 1979 in France, followed by some U.S. 
healthcare institutions, in which 25% of E. faecium iso-
Gentamicin resistance gene aph(3’)-IIIa 0 0 3 1 2 3
 ant(4’)-Ia 0 0 3 1 0 0
 aac(6’)-Ie aph(2’’) 0 0 5 2 2 2
Table III
The association between presence of gentamicin resistance genes and MICs against gentamicin.
MIC (µg/ml)
Gene target 256 512 1024
E. faecalis E. faecium E. faecalis E. faecium E. faecalis E. faecium
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lates displayed the HLGR phenotype and a decade later, 
more than 60% of E. faecium isolates demonstrated this 
phenotype (Kobayashi et al. 2003). 
Nine genes that encode enzymes targeting eight dif-
ferent aminoglycosides have been identified. In most 
cases, the aac(6’)-Ie aph (2’) gene has been found to be 
associated with resistance to aminoglycosides (Ramirez 
and Tolmasky 2010).
Like in this study, the HLGR was reported high 
in other similar studies from Iran, (Emaneini et al. 
2016; Heidari et al. 2017). The studies conducted in 
other countries have also been reported a high rate 
of the HLGR phenotype. Almost in all these studies, 
high rate of HLGR was more prevalent in E. faecalis 
which could be related to its higher prevalence in the 
clinic (Wendelbo et al. 2003; Adhikari, 2010). Thus, 
the prevalence of aph(3’)-IIIa, ant(4’)-Ia and aac(6’)-Ie 
aph(2’) was higher in E. faecalis isolates in comparison 
to E. faecium isolates. 
We could not find any report that study the rela-
tion between the presence of aminoglycosides resist-
ance genes and the HGLR rate. The prevalence of the 
HLGR phenotype and the aminoglycosides resistance 
genes varied in the studies from all over the world (Udo 
et al. 2004). Nowadays, there are several genes confer-
ring aminoglycosides resistance among Enterococci 
including the aph(2’’)-Ic, aph(2’’)-Id, aph(2’’)-Ib genes, 
and the aac(6’)-Ie-aph(2’)-Ia gene is no longer the only 
gentamicin resistance gene (Chow et al. 1997; Tsai et al. 
1998; Kao et al. 2000). Almost all these genes are located 
on transposable elements, which contribute to their easy 
dissemination and this poses a challenge for health sys-
tems. Treatment of HLGR Enterococci is a real problem. 
Recently, few reports suggested using an anti-peptido-
glycan active agent in combination with a membrane 
active agent. Accordingly, a  successful treatment of 
endocarditis caused by E. faecalis of HLGR phenotype 
was demonstrated after administration of daptomycin 
plus ceftaroline (Sakoulas et al. 2013b). Although the 
HLGR Enterococci are predominant in our region, van-
comycin keeps its antimicrobial effect on such strains. 
However, we reported VRE isolates and this could be 
a “red alarm” to our health system, and thus a continu-
ous surveillance using both genetically and phenotypi-
cally methods should be done for this type of resistance.
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